{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:14:17Z","timestamp":1791814457618,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pbio.3001547","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000}}],"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/18\/23\/33512"],"award-info":[{"award-number":["FS\/18\/23\/33512"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00011\/1"],"award-info":[{"award-number":["MC_UU_00011\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>\n                    Large-scale molecular profiling and genotyping provide a unique opportunity to systematically compare the genetically predicted effects of therapeutic targets on the human metabolome. We firstly constructed genetic risk scores for 8 drug targets on the basis that they primarily modify low-density lipoprotein (LDL) cholesterol (HMGCR, PCKS9, and NPC1L1\n                    <jats:italic>)<\/jats:italic>\n                    , high-density lipoprotein (HDL) cholesterol (CETP), or triglycerides (APOC3, ANGPTL3, ANGPTL4, and LPL). Conducting mendelian randomisation (MR) provided strong evidence of an effect of drug-based genetic scores on coronary artery disease (CAD) risk with the exception of ANGPTL3. We then systematically estimated the effects of each score on 249 metabolic traits derived using blood samples from an unprecedented sample size of up to 115,082 UK Biobank participants. Genetically predicted effects were generally consistent among drug targets, which were intended to modify the same lipoprotein lipid trait. For example, the linear fit for the MR estimates on all 249 metabolic traits for genetically predicted inhibition of LDL cholesterol lowering targets HMGCR and PCSK9 was r\n                    <jats:sup>2<\/jats:sup>\n                    = 0.91. In contrast, comparisons between drug classes that were designed to modify discrete lipoprotein traits typically had very different effects on metabolic signatures (for instance, HMGCR versus each of the 4 triglyceride targets all had r\n                    <jats:sup>2<\/jats:sup>\n                    &lt; 0.02). Furthermore, we highlight this discrepancy for specific metabolic traits, for example, finding that LDL cholesterol lowering therapies typically had a weak effect on glycoprotein acetyls, a marker of inflammation, whereas triglyceride modifying therapies assessed provided evidence of a strong effect on lowering levels of this inflammatory biomarker. Our findings indicate that genetically predicted perturbations of these drug targets on the blood metabolome can drastically differ, despite largely consistent effects on risk of CAD, with potential implications for biomarkers in clinical development and measuring treatment response.\n                  <\/jats:p>","DOI":"10.1371\/journal.pbio.3001547","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T14:14:30Z","timestamp":1645798470000},"page":"e3001547","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":309,"title":["Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-2040","authenticated-orcid":true,"given":"Tom G.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-4950","authenticated-orcid":true,"given":"Genevieve M.","family":"Leyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Elsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-8314","authenticated-orcid":true,"given":"George","family":"Davey Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-0879","authenticated-orcid":true,"given":"Michael V.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"pbio.3001547.ref001","unstructured":"World Health Organization. Cardiovasc Dis. 2020. Available from: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases\/#tab=tab_1."},{"issue":"10059","key":"pbio.3001547.ref002","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"R Collins","year":"2016","journal-title":"Lancet"},{"issue":"32","key":"pbio.3001547.ref003","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"BA Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"12","key":"pbio.3001547.ref004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis","volume":"316","author":"MG Silverman","year":"2016","journal-title":"JAMA"},{"issue":"15","key":"pbio.3001547.ref005","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study","volume":"65","author":"BA Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"pbio.3001547.ref006","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"MV Holmes","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"pbio.3001547.ref007","doi-asserted-by":"crossref","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis","volume":"17","author":"TG Richardson","year":"2020","journal-title":"PLoS Med"},{"issue":"2","key":"pbio.3001547.ref008","article-title":"Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice","volume":"6","author":"AV Fuentes","year":"2018","journal-title":"Pharmacy (Basel)."},{"issue":"10170","key":"pbio.3001547.ref009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"C. Cholesterol Treatment Trialists","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"pbio.3001547.ref010","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"CP Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"pbio.3001547.ref011","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease","volume":"377","author":"Group HTRC","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"pbio.3001547.ref012","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2174\/0929867324666170609081612","article-title":"APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia","volume":"25","author":"J Schmitz","year":"2018","journal-title":"Curr Med Chem"},{"issue":"5","key":"pbio.3001547.ref013","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia","volume":"373","author":"D Gaudet","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"pbio.3001547.ref014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease","volume":"377","author":"FE Dewey","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"pbio.3001547.ref015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"U Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"pbio.3001547.ref016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41569-019-0157-6","article-title":"What is \u2019LDL cholesterol\u2019?","volume":"16","author":"MV Holmes","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"pbio.3001547.ref017","article-title":"Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development","author":"MV Holmes","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"pbio.3001547.ref018","article-title":"Using Mendelian Randomization to Improve the Design of Randomized Trials","author":"BA Ference","year":"2021","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"12","key":"pbio.3001547.ref019","doi-asserted-by":"crossref","first-page":"e3000572","DOI":"10.1371\/journal.pbio.3000572","article-title":"Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition","volume":"17","author":"J Kettunen","year":"2019","journal-title":"PLoS Biol"},{"issue":"6","key":"pbio.3001547.ref020","doi-asserted-by":"crossref","first-page":"e1009575","DOI":"10.1371\/journal.pgen.1009575","article-title":"Causal inference for heritable phenotypic risk factors using heterogeneous genetic instruments","volume":"17","author":"J Wang","year":"2021","journal-title":"PLoS Genet"},{"issue":"12","key":"pbio.3001547.ref021","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease","volume":"374","author":"FE Dewey","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"pbio.3001547.ref022","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/sim.6835","article-title":"Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods","volume":"35","author":"S Burgess","year":"2016","journal-title":"Stat Med"},{"issue":"7","key":"pbio.3001547.ref023","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"S Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"issue":"22","key":"pbio.3001547.ref024","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes","volume":"375","author":"BA Ference","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"pbio.3001547.ref025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease","volume":"321","author":"BA Ference","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"pbio.3001547.ref026","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk","volume":"318","author":"BA Ference","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"pbio.3001547.ref027","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137 895 Individuals","volume":"38","author":"AB Wulff","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"pbio.3001547.ref028","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/eurheartj\/ehaa972","article-title":"Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis","volume":"42","author":"Q Wang","year":"2021","journal-title":"Eur Heart J"},{"key":"pbio.3001547.ref029","article-title":"Dominant role of abdominal adiposity in circulating lipoprotein, lipid, and metabolite levels in UK Biobank: Mendelian randomization study","author":"JA Bell","year":"2021","journal-title":"medRxiv"},{"key":"pbio.3001547.ref030","article-title":"New drugs coming up in the field of lipid control","volume":"19","author":"Mendes PFAPP Moura JMSP","year":"2020","journal-title":"e-Journal of Cardiology. Practice"},{"issue":"3","key":"pbio.3001547.ref031","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MOL.0000000000000679","article-title":"The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?","volume":"31","author":"LF Reeskamp","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"pbio.3001547.ref032","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/d41573-021-00047-1","article-title":"FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication","volume":"20","author":"A. Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"pbio.3001547.ref033","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drudis.2016.10.007","article-title":"Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases","volume":"22","author":"WJ Geldenhuys","year":"2017","journal-title":"Drug Discov Today"},{"issue":"10","key":"pbio.3001547.ref034","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2015.12.060","article-title":"Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase","volume":"67","author":"P Wurtz","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"pbio.3001547.ref035","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","article-title":"Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment","volume":"138","author":"E Sliz","year":"2018","journal-title":"Circulation"},{"key":"pbio.3001547.ref036","article-title":"Triangulating Evidence through the Inclusion of Genetically Informed Designs.","author":"MR Munafo","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"pbio.3001547.ref037","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/ije\/dyy262","article-title":"An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings","volume":"48","author":"E Sanderson","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"3","key":"pbio.3001547.ref038","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1373\/clinchem.2018.291104","article-title":"A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease","volume":"65","author":"P Mohammadi-Shemirani","year":"2019","journal-title":"Clin Chem"},{"issue":"3","key":"pbio.3001547.ref039","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1373\/clinchem.2018.296806","article-title":"Can Mendelian Randomization Shift into Reverse Gear?","volume":"65","author":"MV Holmes","year":"2019","journal-title":"Clin Chem"},{"issue":"3","key":"pbio.3001547.ref040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41431-018-0301-5","article-title":"Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile","volume":"27","author":"LL Blauw","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"pbio.3001547.ref041","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2666-7568(21)00086-6","article-title":"Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives","volume":"2","author":"TG Richardson","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"10","key":"pbio.3001547.ref042","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"M Nikpay","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"pbio.3001547.ref043","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"FJ Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"pbio.3001547.ref044","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.","volume":"12","author":"C Sudlow","year":"2015","journal-title":"PLoS Med."},{"issue":"7726","key":"pbio.3001547.ref045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"C Bycroft","year":"2018","journal-title":"Nature"},{"issue":"3","key":"pbio.3001547.ref046","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/ng.3190","article-title":"Efficient Bayesian mixed-model analysis increases association power in large cohorts","volume":"47","author":"PR Loh","year":"2015","journal-title":"Nat Genet"},{"issue":"7422","key":"pbio.3001547.ref047","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11632","article-title":"An integrated map of genetic variation from 1,092 human genomes","volume":"491","author":"C Genomes Project","year":"2012","journal-title":"Nature"},{"issue":"1","key":"pbio.3001547.ref048","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41467-019-13921-9","article-title":"A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome","volume":"11","author":"TG Richardson","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"pbio.3001547.ref049","article-title":"Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population","author":"Nightingale Health UKBI","year":"2021","journal-title":"elife"},{"issue":"11","key":"pbio.3001547.ref050","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41588-018-0241-6","article-title":"Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps","volume":"50","author":"A Mahajan","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"pbio.3001547.ref051","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1038\/s41467-020-19478-2","article-title":"Collider bias undermines our understanding of COVID-19 disease risk and severity","volume":"11","author":"GJ Griffith","year":"2020","journal-title":"Nat Commun"},{"key":"pbio.3001547.ref052","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1467-985X.2010.00676_9.x","article-title":"ggplot2: Elegant Graphics for Data Analysis","volume":"174","author":"C. Ginestet","year":"2011","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"pbio.3001547.ref053","doi-asserted-by":"crossref","first-page":"252","DOI":"10.12688\/wellcomeopenres.16374.2","article-title":"MendelianRandomization v0.5.0: updates to an R package for performing Mendelian randomization analyses using summarized data","volume":"5","author":"JR Broadbent","year":"2020","journal-title":"Wellcome Open Res"}],"updated-by":[{"DOI":"10.1371\/journal.pbio.3001547","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000}}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T13:49:00Z","timestamp":1646833740000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001547"}},"subtitle":[],"editor":[{"given":"Jason W.","family":"Locasale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3001547","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.06.21261699","asserted-by":"object"}]},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}